ICAM1 and type 2 diabetes mellitus: Sympathetic blockade by administration of an alpha-1- and beta-adrenoreceptor antagonist attenuated the expression of ICAM-1, and leukocyte-endothelium interaction in a rat model of type 2 diabetes [36].